Caroline Hego
A5039058967- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Advanced Breast Cancer Therapies
- Advanced Biosensing Techniques and Applications
- Ocular Oncology and Treatments
- Epigenetics and DNA Methylation
- Chromosomal and Genetic Variations
- Liver Disease and Transplantation
- Lung Cancer Research Studies
- Cell Adhesion Molecules Research
- Microtubule and mitosis dynamics
- Liver Disease Diagnosis and Treatment
- Cancer-related Molecular Pathways
- RNA Research and Splicing
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Hepatitis Viruses Studies and Epidemiology
- Estrogen and related hormone effects
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gene expression and cancer classification
- Immune cells in cancer
- Extracellular vesicles in disease
- Cancer Immunotherapy and Biomarkers
Institut Curie
2010-2024
Inserm
2021-2024
Université Paris Sciences et Lettres
2017-2022
Hôpital Saint-Louis
2013
In nonmetastatic triple-negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.Ten milliliters of plasma were collected at 4 time points: before NCT; 1 cycle; surgery; surgery. Customized droplet digital PCR (ddPCR) assays used track protein p53 (TP53) mutations previously characterized in tissue by massively parallel sequencing...
Abstract Circulating tumor cells (CTCs) and circulating DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis treatment efficacy in breast cancer. We prospectively evaluated the clinical validity of quantifying both CTCs (CellSearch) ctDNA (targeted next-generation sequencing). Their combined value as prognostic early monitoring markers was assessed 198 HER2-negative metastatic cancer patients. All patients were included prospective multicenter UCBG study COMET...
In a prospective study (NCT02866149), we assessed the efficacy of fulvestrant and everolimus in CDK4/6i pre-treated mBC patients circulating tumor DNA (ctDNA) changes throughout therapy. Patients treated with had their ctDNA at baseline, after 3-5 weeks disease progression. Somatic mutations were identified archived tissues by targeted NGS tracked cell-free droplet digital PCR. detection was then associated clinicopathological characteristics patients' progression-free survival (PFS),...
<p>Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not confounding factor in this study</p>
<p>Fig S5. Comparison of tumor and plasma paired samples</p>
<p>Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts</p>
<p>Fig S11. 2 step-models integrating CNA signal extracted from DIAMOND data</p>
<p>Fig S6. Classifier performances: feature types, calculation parameters, cancer subtypes and stages</p>
<p>Fig S8. DIAMOND profiles and performances in the validation versus discovery cohorts</p>
<p>Fig S10. Comparison of multiple classifiers (expert, all, stack and blind models) prognostic value L1PA hypomethylation</p>
<p>Fig S5. Comparison of tumor and plasma paired samples</p>
<p>Fig S3. Preparation of L1PA targeted bisulfite sequencing libraries and analysis workflow</p>
<p>Fig S1. cfDNA extraction methods did not impact the L1PA methylation patterns</p>
<p>Fig S9. Age has a minor effect on L1PA DNA methylation patterns and is not confounding factor in this study</p>
<p>Fig S4. DIAMOND features: CpG calling and contribution of CG positions or haplotypes</p>
<p>Fig S2. Methylation profiles obtained with bisulfite or enzymatic conversion are similar</p>
<div>AbstractPurpose:<p>The detection of ctDNA, which allows noninvasive tumor molecular profiling and disease follow-up, promises optimal individualized management patients with cancer. However, detecting small fractions DNA released when the burden is reduced remains a challenge.</p>Experimental Design:<p>We implemented new, highly sensitive strategy to detect bp resolution methylation patterns from plasma assessed potential hypomethylation long interspersed nuclear...
<p>Fig S6. Classifier performances: feature types, calculation parameters, cancer subtypes and stages</p>
<p>Fig S11. 2 step-models integrating CNA signal extracted from DIAMOND data</p>
<p>Fig S4. DIAMOND features: CpG calling and contribution of CG positions or haplotypes</p>
<p>Fig S2. Methylation profiles obtained with bisulfite or enzymatic conversion are similar</p>
<p>Fig S3. Preparation of L1PA targeted bisulfite sequencing libraries and analysis workflow</p>